MedTrace Logo

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

NCT07064486 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 477

Last updated 2025-10-28

No results posted yet for this study

Summary

This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes

Conditions

  • Type 2 Diabetes (T2DM)

Interventions

DRUG

BGM0504

Administered SC

DRUG

BGM0504

Administered SC

DRUG

Semaglutide

Administered SC

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-04
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07064486 on ClinicalTrials.gov